ANI Pharmaceuticals (NASDAQ:ANIP) Stock Gets Price Target Bump from Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP) had its price objective upped by Guggenheim from $119.00 to $121.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Guggenheim‘s price target would indicate a potential upside of 76.08% from the stock’s previous close.

Several other research analysts have also recently issued reports on ANIP. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price target for the company. Canaccord Genuity Group lowered their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Finally, Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $100.00.

ANI Pharmaceuticals Trading Down 1.3%

ANIP stock traded down $0.90 during mid-day trading on Friday, reaching $68.72. The company had a trading volume of 113,309 shares, compared to its average volume of 381,472. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The company has a market capitalization of $1.58 billion, a PE ratio of 14.85, a price-to-earnings-growth ratio of 2.31 and a beta of 0.45. The firm has a 50 day moving average of $72.65 and a 200 day moving average of $77.41. ANI Pharmaceuticals has a 12 month low of $68.79 and a 12 month high of $95.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.18 by $0.52. The firm had revenue of $290.78 million during the quarter, compared to the consensus estimate of $280.59 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company’s revenue was up 27.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.04 earnings per share. On average, equities analysts predict that ANI Pharmaceuticals will post 7.76 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $71.89, for a total value of $388,206.00. Following the transaction, the chief executive officer owned 333,689 shares in the company, valued at approximately $23,988,902.21. This represents a 1.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the sale, the senior vice president owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. The trade was a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 30,412 shares of company stock valued at $2,220,970. 8.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. KBC Group NV acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Versant Capital Management Inc grew its holdings in shares of ANI Pharmaceuticals by 103.3% during the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 217 shares during the period. Eurizon Capital SGR S.p.A. acquired a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth about $32,000. USA Financial Formulas acquired a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth about $39,000. Finally, Sterling Capital Management LLC increased its position in shares of ANI Pharmaceuticals by 850.0% during the 3rd quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company’s stock worth $50,000 after purchasing an additional 612 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals News Summary

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Q3 results beat expectations: ANI reported adjusted earnings of $2.70 per share versus consensus of about $2.18, while revenue of $290.78 million exceeded estimates of $280.59 million. Revenue increased 27.6% year over year, and EPS rose from $2.04. The earnings beat and growth are supportive of the stock. ANI Pharmaceuticals Q3 2026 results
• Positive Sentiment: Proposed Egetis acquisition would expand rare-disease business: ANI made a recommended public offer valued at approximately SEK 5.6 billion (about $560 million) for Swedish biotech Egetis Therapeutics. The deal could broaden ANI’s rare-disease portfolio and growth opportunities. ANI Pharmaceuticals Egetis offer
• Neutral Sentiment: Acquisition adds execution and financial considerations: The offer’s strategic rationale is clear, but investors will weigh its cost, funding implications and integration alongside the potential benefits. ANI offer to acquire Egetis
• Negative Sentiment: Shares remain near their one-year low: That weak trading context indicates investor caution persists despite the earnings beat; the acquisition’s cost and execution may be among the issues investors are considering.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.